-
Amitkumar Mehta, MD; University of Alabama at Birmingham O’Neal Comprehensive Cancer Center; 5Live #ASH21
8:55
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Ann LaCasce, MD; Dana-Farber Cancer Institute; 5Live #ASH21
5:21
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Matthew Lunning, DO, FACP; University of Nebraska Medical Center; 5Live #ASH21
4:55
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Loretta Nastoupil, MD; The University of Texas MD Anderson Cancer Center; 5Live #ASH21
6:24
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Appropriate indications and methods of administration of CNS prophylaxis in aggressive NHL_Victor Orellana-Noia, MD; #DDHO2021
1:36
-
Risk stratification and therapy for high-grade NHL_Kristie Blum, MD; #DDHO2021
2:27
-
CAR T-cell Therapy in NHL_Noretta Nastoupil, MD; #SOHO2021
20:38
-
Ranjana Advani, MD; Stanford University #BtC_ASCO21
15:14
Dr. Ranjana Advani shares strategies for Integrating Recently Approved Therapies for B-cell NHL Into Practice.
-
John P. Leonard, MD; Weill Cornell Medicine #BtC_ASCO21
16:48
Dr. John Leonard discusses Recently Presented Data of Clinical Trials in Patients with NHL.
-
Julie M. Vose, MD, MBA; University of Nebraska Medical Center; 5Live; #ASCO2021
4:06
-
John Leonard, MD; Weill Cornell Medicine New York Presbyterian Hospital; 5Live; #ASCO2021
6:39
- Next Page
ABOUT
Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.
The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.
CONNECT
© Copyright 2021 Bio Ascend, a Vaniam Group company